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Infection of fibroblasts by human cytomegalovirus (HCMV) rapidly activates the NF-nB signaling pathway, which we documented promotes
efficient transactivation of the major immediate-early promoter (DeMeritt, I.B., Milford, L.E., Yurochko, A.D. (2004). Activation of the NF-nB
pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter. J. Virol. 78,
4498–4507). Because a second, sustained increase in NF-nB activity following the initial phase of NF-nB activation was also observed, we
investigated the role that this prolonged NF-nB activation played in viral replication and late gene expression. We first investigated HCMV
replication in cells in which NF-nB activation was blocked by pretreatment with NF-nB inhibitors: HCMV replication was significantly decreased
in these cultures. A decrease in replication was also observed when NF-nB was inhibited up to 48 h post-infection, suggesting a previously
unidentified role for NF-nB in the regulation of the later class of viral genes.
D 2005 Elsevier Inc. All rights reserved.Keywords: HCMV; NF-nB; MIEP; Replication; Late gene expression; Aspirin; MG-132; BAY11Introduction
Infection of immunocompromised individuals with human
cytomegalovirus (HCMV) often leads to severe and/or fatal
disease (Crumpacker, 2000). AIDS patients, transplant recipi-
ents, and congenitally infected neonates represent the primary
groups at risk for developing severe complications related to
HCMV infection (Pass, 2001). On the other hand, HCMV
infection of immunocompetent individuals is generally asymp-
tomatic, although it can cause infectious mononucleosis
(Klemola and Kaariainen, 1965), and evidence now suggests
that HCMV infection is associated with the development of
cardiovascular disease including atherosclerosis and restenosis
(Bruggeman, 1999; Degre, 2002; Epstein et al., 1999b;
Streblow et al., 2001). Because HCMV pathogenesis is usually0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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understanding the factors involved in viral replication and gene
expression is critical for combating HCMV-related disease.
A temporal cascade of viral gene expression occurs
following infection in which immediate-early (IE), early, and
late genes are transcribed in order (Mocarski and Courcelle,
2001). IE gene transcription is controlled by the major
immediate-early promoter (MIEP) (Boshart et al., 1985;
Stenberg et al., 1984, 1985; Stinski et al., 1983; Thomsen et
al., 1984). Transactivation of the HCMV MIEP is essential for
viral gene expression and replication (Bresnahan and Shenk,
2000; Isomura and Stinski, 2003; Isomura et al., 2004; Meier
and Pruessner, 2000). Because numerous cellular transcription
factor binding sites were found in the enhancer region of the
MIEP, it was hypothesized that induced cellular factors played
a predominant role in the transactivation of this promoter. Early
work using deletion mutants of the MIEP supported this
hypothesis (Cherrington and Mocarski, 1989; Sambucetti et al.,
1989). In addition, because the region of the promoter
containing four NF-nB binding sites was needed for maximal06) 15 – 31
www.e
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transcription factor NF-nB could be an important regulatory
factor driving viral gene expression.
Classical NF-nB is a heterodimeric complex consisting of
two subunits, p50 and p65, that is normally sequestered by its
inhibitors, the InBs, in the cytosol (Karin and Ben-Neriah,
2000). Following activation of cellular signaling cascades, the
InB kinase (IKK) complex is activated, resulting in the
phosphorylation of the InB proteins which, in turn, leads to
the ubiquitination and subsequent degradation of the InB
proteins by the 26S proteosome complex (Chen et al., 1995;
DiDonato et al., 1996). Once freed from its inhibitor, NF-nB
translocates to the nucleus and transactivates NF-nB responsive
genes (Chen and Greene, 2004).
NF-nB activation takes place during two distinct phases
following HCMV infection of fibroblasts (Johnson et al., 2001;
Kowalik et al., 1993; Yurochko et al., 1995). The first phase of
NF-nB activation occurs immediately following infection (as
early as 5 min after viral binding) and was demonstrated to be
the result of the release of preformed stores of NF-nB mediated
by the binding of HCMV glycoproteins to their cellular
receptors (Yurochko et al., 1995, 1997a). The second increase
in NF-nB activation was observed 8 to 12 h post-infection (hpi)
and was demonstrated to be the result of de novo synthesis of
NF-nB proteins (Yurochko et al., 1995). We previously
presented evidence that suggested that the initial phase of
NF-nB activation promoted the efficient transactivation of the
MIEP and the production of IE genes (DeMeritt et al., 2004).
This study showed that transactivation of the HCMV MIEP
was significantly reduced in fibroblasts in which NF-nB
activation was inhibited. In addition, it was demonstrated that
the IKK complex was activated in response to HCMV
infection, providing a mechanism for the rapid dysregulation
of NF-nB activity reported by us (Yurochko and Huang, 1999;
Yurochko et al., 1995, 1997a, 1997b) and others (Johnson et
al., 2001; Kowalik et al., 1993; Sambucetti et al., 1989). This
work is supported by a recent report by Caposio et al. (2004)
who observed that IKKh was required for HCMV-mediated
NF-nB activation and for initiation of the viral life cycle.
In contrast to the reports discussed above, other studies
suggested that NF-nB activation was not required for the
transactivation of the MIEP and HCMV replication (Benedict
et al., 2004; Eickhoff and Cotten, 2005; Isomura et al., 2004).
The reason for these differences is unknown but may representFig. 1. Inhibition of NF-nB activity blocked HCMV replication. (A) HEL fibroblas
AM), or DMSO (drug solvent) for 1 h prior to infection with GFP-HCMV (MOI
microscopy. Higher levels of GFP-expressing cells were present in fibroblast cultur
inhibitory compounds. Mock-infected cells showed no GFP expression (data no
Quantification of the fluorescence intensity of confluent fibroblast cultures pretreated
1 h prior to infection with GFP-HCMV (MOI 3–5). Replicate cultures were mo
measured using a FLUOstar OPTIMA fluorescence plate reader and was measured
deviation) in fluorescence intensity relative to mock-infected cells. The data are
Student’s t test and demonstrate a significant increase ( P < 0.005) in DMSO-treated
nB inhibitory drugs. The aspirin solvent (1 M Tris) had no effect on GFP expressio
MG-132 prior to infection inhibits HCMV genomic replication. HEL fibroblasts
Fibroblasts pretreated with the drugs, and untreated fibroblasts were infected with
performed using an HCMV-specific 32P-labeled DNA probe. Mock represents
representative experiment is shown.differences in the cell lines or in the systems used. Because a
complete appreciation of the regulation of viral gene expres-
sion and replication is important for our understanding of
HCMV pathogenesis, these discrepancies warrant further
investigation into the role that NF-nB plays in the HCMV life
cycle.
During the second phase of NF-nB activation, nuclear NF-
nB levels remain elevated throughout the course of the
infection (Yurochko et al., 1995). We propose that this
prolonged activation of NF-nB is involved in viral pathogen-
esis through the efficient activation of required viral events
following IE gene expression. A direct role for long-term
activation of NF-nB in the viral life cycle has not been
identified. Studies presented here support our previous findings
regarding the role NF-nB plays at IE times of HCMV infection
and now suggest a role for the late phase of NF-nB activation
in viral replication and the production of late HCMV proteins.
We demonstrated that inhibition of NF-nB (1) prevented
efficient HCMV genomic replication, (2) blocked production
of late proteins, and (3) significantly impaired progeny virus
release from infected fibroblasts. We also documented that
delayed inhibition of NF-nB, even as late as 48 hpi, still
inhibited viral replication. Thus, we propose a direct role for
NF-nB at late times of HCMV replication independent of
MIEP transactivation. This study, coupled with our previously
published report (DeMeritt et al., 2004), identifies the NF-nB
pathway as an important factor in mediating multiple steps in
the HCMV life cycle in fibroblasts and suggests that targeting
the NF-nB pathway may provide an effective means to
ameliorate HCMV-mediated disease.
Results
Inhibition of NF-jB activity blocked HCMV replication
We reported that IE1-72 and IE2-86 gene and protein
expression were significantly decreased and delayed in cells in
which NF-nB activation was inhibited with aspirin and MG-
132 (DeMeritt et al., 2004). Because the IE proteins act as
transcriptional transactivators and control the expression of
early genes required for viral DNA synthesis, we hypothesized
that HCMV replication would be impaired when NF-nB
activation was blocked. To investigate the effects of NF-nB
inhibition on HCMV replication, a Toledo strain of HCMVts were grown to confluency and pretreated with aspirin (3 mM), MG-132 (2.5
3–5). GFP expression was monitored at 48, 72, and 96 hpi by fluorescence
es treated with drug solvent alone compared to cultures pretreated with NF-nB
t shown). A representative experiment from multiple repeats is shown. (B)
with aspirin (3 mM), MG-132 (2.5 AM), DMSO, or left untreated (no drug) for
ck infected for use as a negative control (Mock). Fluorescence intensity was
every 24 h after infection. Data are displayed as the fold-increase (Tstandard
the means of three independent experiments. P values were calculated using
and untreated (no drug) cultures when compared to cultures treated with the NF-
n and is not shown in the figure. (C) Treatment of fibroblasts with aspirin and
were pretreated with aspirin (3 mM), MG-132 (2.5 AM), or DMSO for 1 h.
HCMV (MOI 3–5). Total cellular DNA was harvested at 72 hpi and dot blots
uninfected fibroblasts. The experiment was repeated with similar results; a
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1999). HEL fibroblasts were pretreated with aspirin or MG-132
for 1 h prior to infection with GFP-HCMV. Aspirin is a general
inhibitor of NF-nB that targets the IKKh protein (Kopp and
Ghosh, 1994; Pierce et al., 1996; Yin et al., 1998), while MG-
132 specifically inhibits the 26S proteosome complex therebypreventing the degradation of the InB proteins (Palombella et
al., 1994); both compounds prevent translocation of active NF-
nB to the nucleus. Fibroblasts expressing GFP were visualized
by fluorescence microscopy at 48, 72, and 96 hpi to determine
the level of replicating virus in infected fibroblasts (Fig. 1A).
Cultures pretreated with either aspirin or MG-132 showed
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compared to cells pretreated with the drug solvents alone. Only
the DMSO control is shown in Fig. 1A, however, no
differences were observed by microscopy between the
DMSO-treated infected cells and the untreated infected cells.
The decrease in GFP expression from drug-treated cells was
not due to toxic effects of the drugs, as greater than 95% of
cells were viable at the latest time point tested, as determined
by trypan blue exclusion dye staining (data not shown) and
TUNEL staining (Supplemental Fig. 1).
To quantify the difference in viral replication among the
experimental groups, total fluorescent intensity of tissue culture
plates containing GFP-HCMV-infected fibroblasts was deter-
mined using a fluorescence plate reader (Fig. 1B). Confluent
HEL fibroblasts were pretreated with aspirin, MG-132, or drug
solvent alone, and infected with GFP-HCMVor mock infected.
Total fluorescence intensity of each sample was measured
every 24 h. By 120 hpi, infected fibroblast cultures treated with
DMSO alone exhibited an average 75-fold increase in
fluorescence intensity over mock-infected cells. In comparison,
infected cultures pretreated with aspirin or MG-132 showed
significantly decreased levels of fluorescence intensity: only 2-
and 5-fold increases over mock-infected cells were observed,
respectively. Samples treated with DMSO alone exhibited a
slight but reproducible increase in fluorescence intensity over
untreated cultures.
It was previously demonstrated that GFP expression directly
correlated with viral replication (Iwata et al., 1999). However,
because GFP expression was under the control of the cellular
elongation factor 1a promoter in the recombinant Toledo strain
used (Iwata et al., 1999), we wanted to rule out the possibility
that the NF-nB inhibitory compounds blocked transcription
from this promoter instead of inhibiting viral replication. To
confirm that fluorescence intensity was an accurate measure-
ment of HCMV replication in our system, dot blot analyses
were performed on untreated cells, or cells pretreated with
aspirin, MG-132, or the drug solvent DMSO for 1 h prior to
infection with GFP-HCMV. Total cellular DNA was harvested
at 72 hpi, and dot blot analysis was performed using an
HCMV-specific 32P-labeled probe (Fig. 1C). Compared to
untreated cells or cells treated with DMSO alone, viral
replication was inhibited in cells treated with aspirin or MG-
132 prior to infection, suggesting that HCMV genomic
replication is regulated in a positive manner by NF-nB.
Inhibition of NF-jB activity blocked the production of progeny
virus
We next investigated whether the inhibition of NF-nB
activity blocked progeny virus production. Fibroblast cultures
were grown to confluency in 6-well tissue culture dishes and
pretreated with aspirin, MG-132, or drug solvents for 1 h prior
to infection with GFP-HCMV. Media were changed every 24 h,
and fresh drugs were added at these times. Supernatant was
collected from infected cells at 96 hpi, and infectious unit
assays were performed (Figs. 2A and B). Production of
progeny virus was dramatically inhibited when cells werepretreated with the NF-nB inhibitory drugs, as demonstrated by
the increased number of GFP-positive cells observed in wells
infected with supernatant from cells treated with DMSO alone
compared to cells treated with aspirin or MG-132 (Fig. 2A).
Fig. 2A represents an experiment where the supernatant from
aspirin or MG-132 treated cells was diluted 1:10 (the lowest
dilution performed). As seen in the figure, no GFP-positive
cells were observed in wells treated with aspirin or MG-132,
suggesting that these compounds completely inhibited viral
replication for up to 8 days post-infection (the last time point
tested). In contrast, cultures treated with drug solvent alone
reached maximal titers of 4.0  105 infectious units per
milliliter by seven days post-infection (Fig. 2B). No significant
differences were seen in the production of progeny virus
between DMSO-treated infected cells and untreated infected
cells (data not shown). These results support the observation
that NF-nB activity is needed for efficient viral DNA
replication and progeny virus production.
The residual levels of NF-nB-inhibitory drugs remaining in
the experimental samples following serial dilution could have
an effect on virus replication in our infectious unit assays. To
control for this possibility, equal levels of NF-nB inhibitory
compounds were added to the supernatants collected from the
untreated, infected cultures prior to dilution. The addition of
NF-nB inhibitory compounds to these samples had no effect on
the number of GFP-expressing cells observed in our assays
(data not shown).
Inhibition of NF-jB activity at later times of infection blocked
viral replication
NF-nB activation is strongly induced in two phases
following HCMV infection (Yurochko et al., 1995). We
previously demonstrated that the rapid initial phase of NF-nB
activation efficiently transactivated the MIEP and drove the
production of the IE proteins (DeMeritt et al., 2004). The
function of the second (later) phase of NF-nB activation in the
HCMV life cycle remains unknown. Transcription from the
MIEP can be inhibited by viral proteins early after infection
(Cherrington et al., 1991; Hermiston et al., 1990; Liu et al.,
1991; Pizzorno and Hayward, 1990; Pizzorno et al., 1988;
Stenberg et al., 1990), and, although IE1-72 protein is very
stable, new IE1-72 protein synthesis does not occur after 12 hpi
(Poma et al., 1996). Therefore, it is unlikely that the prolonged
activation of NF-nB induced by HCMV functions to transacti-
vate this promoter at later times of infection. Thus, we
hypothesized that the second phase of NF-nB activation plays
a role in HCMV replication independently of MIEP transacti-
vation. To test this hypothesis, we examined viral replication
when NF-nB activity was blocked at early and late times of
infection using the NF-nB inhibitors.
To measure viral replication, fibroblasts were infected with
GFP-HCMV, and drugs were applied at 24 or 48 hpi; control
cultures were pretreated with NF-nB inhibitors for one hour
prior to infection. For all experiments, media were changed,
and fresh drugs added every 24 h. Total fluorescence intensity
of each well was measured using a fluorescence plate reader.
Fig. 2. Inhibition of NF-nB activity blocked the production of progeny virus. HEL fibroblasts were grown to confluency in 6-well tissue culture dishes and pretreated
with 2 ml of Eagle’s MEM containing aspirin (3 mM), MG-132 (2.5 AM) or DMSO and infected with GFP-HCMV (MOI 3–5), or mock infected. Media were
changed every 24 h with MEM containing fresh drugs. Supernatant from the different culture conditions was collected at the times indicated following infection, and
serial dilutions were performed. Aliquots from each of the serial dilutions were added to fresh HEL fibroblasts grown to confluency in 24-well tissue culture dishes
and incubated overnight. Cultures were then washed with PBS and overlayed with methylcellulose. (A) Infected cells were visualized by fluorescence microscopy
(101 dilution shown). (B) The total number of GFP-expressing cells at each dilution was counted at 96 hpi to determine the virus titer (displayed as infectious units
(IU) of virus per milliliter). To control for the possibility that residual drugs in the supernatant collected from cultures treated with aspirin and MG-132 negatively
affected the virus titers, drugs were added to untreated, but infected supernatants prior to performing serial dilutions. No decrease in viral titers was observed when
drugs were added to untreated supernatants prior to dilution (data not shown).Mock represents uninfected fibroblasts treated identically to experimental samples. The
experiment was repeated with similar results, and a representative experiment is shown.
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blocked HCMV replication even when the drugs were added as
late as 48 hpi. In experiments examining the inhibition of NF-
nB by aspirin (Fig. 3A), solvent alone-treated infected cellsexhibited a 46-fold increase in fluorescence intensity over
mock-infected cells when measured at 120 hpi; when aspirin
was added at 24 or 48 hpi, only 19-fold (59% decrease) and 27-
fold (41% decrease) increases in fluorescence intensity over
Fig. 3. Inhibition of NF-nB activity at later times of infection blocked viral replication. HEL fibroblasts were treated with (A) aspirin (3 mM) or (B) MG-132 (2.5
AM) either 1 h prior to infection, 24 hpi, or 48 hpi with GFP-HCMV (MOI 3–5). Replicate cultures were either mock infected, treated with the solvent (DMSO or
Tris), or left untreated. Fluorescence intensity of cultures was measured every 24 h following infection. Results are displayed as fold-increase (Tstandard deviation) in
fluorescence intensity of GFP-HCMV-infected cells over mock-infected cells. The data are the means of three independent experiments. P values were calculated
using Student’s t test and demonstrate a significant increase ( P < 0.005) in viral replication following infection when compared to cultures to which NF-nB
inhibitory drugs were added 24 or 48 hpi. (C) Western blot analysis demonstrating that IE proteins were maximally produced at 24 hpi and 48 hpi. HEL fibroblasts
were infected with GFP-HCMV, or mock infected, and total cell lysates were harvested at the times indicated. Western blot analyses were performed using
monoclonal antibodies specific for IE1-72 and a-tubulin (as a loading control). Mock represents uninfected fibroblasts. All experiments were repeated with similar
results. Representative experiments are shown.
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infected cells showed an identical pattern of replication when
compared to untreated infected cells (data not shown).
Similarly, when MG-132 was added to cells after 24 or 48
hpi (Fig. 3B), only respective 13-fold and 19-fold increases in
fluorescence intensity (76% and 66% decreases, respectively)
were observed at 96 hpi when compared to mock-infected
cells; cells treated with drug solvent alone exhibited a 56-fold
increase in fluorescence intensity over mock-infected cells at
the same time points. Again, a slight increase in replication was
observed in DMSO-treated infected cells when compared to
untreated infected cells. Similar results were observed when
cells were pretreated, treated at 24 hpi, or at 48 hpi with
lactacystin, a proteasome inhibitor mechanistically similar to
MG-132 (Supplemental Fig. 2). In aspirin, MG-132, and
lactacystin-treated cultures, fluorescence intensity increased
the later the drug was added but remained significantly lower
than untreated cultures or cultures treated with drug solvents
alone.
IE proteins are normally synthesized within hours of
infection (Blanton and Tevethia, 1981; Poma et al., 1996;
Stenberg et al., 1989) and play a critical role in early gene
production and viral replication (Gawn and Greaves, 2002;
Greaves and Mocarski, 1998; Heider et al., 2002; Marchini et
al., 2001; Mocarski et al., 1996; Sanchez et al., 2002; White
et al., 2004). Because we previously demonstrated that NF-nB
was important for efficient production of IE proteins
(DeMeritt et al., 2004), a delay in the HCMV life cycle in
our system could account for the decrease in viral replication
observed upon addition of NF-nB inhibitors. To measure the
kinetics of IE protein synthesis, Western blot analysis was
performed on infected cell lysates harvested at various times
post-infection using antibodies specific for IE1-72 (Fig. 3C).
These data demonstrate that by 6 hpi, IE1-72 reached
maximal levels, consistent with previous reports (Blanton
and Tevethia, 1981; Bresnahan et al., 2000; Stenberg et al.,
1989). The maximal presence of IE1-72 at 24 and 48 hpi
suggests that addition of NF-nB inhibitors at late times of
infection plays an important role in viral replication,
independent of IE protein synthesis.
To measure progeny virus release in the presence of NF-nB
inhibitory drugs at early and late times of infection, supernatant
was collected from infected cells, and infectious unit assays
were performed to quantify virus released from untreated cells
or cells treated with the NF-nB inhibitory drugs at (a) 1 h prior
to infection, (b) 24 hpi, or (c) 48 hpi. Confluent fibroblast
cultures were infected with serially diluted supernatants
collected from experimental samples and, as demonstrated in
Fig. 4A, GFP-expressing cells were examined by fluorescence
microscopy (101 dilution is shown in Fig. 4A). Viral titers
were also calculated (Fig. 4B). These experiments demonstrat-
ed a significant reduction in the amount of virus released from
cells treated with compounds that inhibit NF-nB activation,
even when these compounds were added as late as 48 hpi.
Release of progeny virus from cultures treated with drugs
beginning at 24 hpi exhibited a five-log decrease in virus titers
when compared to DMSO-treated cultures; similar results wereobserved when cultures were pretreated with the NF-nB
inhibitory drugs. Cultures treated with aspirin and MG-132 at
48 hpi showed an approximate three-log decrease in virus titers
when compared to cultures treated with drug solvent alone
(Fig. 4B). As shown in Fig. 4B, no differences were seen in
viral titers in untreated infected cells and DMSO-treated
infected cells. The Tris solvent control also showed no effect
(data not shown). These data suggested that inhibition of NF-
nB activation at late times of infection largely prevented
progeny virus production from infected cells.
HCMV late protein expression was decreased following NF-jB
inhibition at later times of infection
To expand our study into the role that NF-nB plays at late
times of HCMV infection, we next investigated whether
production of late proteins important for HCMV biology was
affected by the addition of NF-nB inhibitory compounds at
late times of infection. To investigate the effects of aspirin
and MG-132 on synthesis of viral late proteins, we performed
Western blot analysis using antibodies specific for gB and
pp65. Assays were performed on total cell lysates harvested at
72 hpi from HEL fibroblasts infected with the HCMV Towne/
E strain (MOI 3 to 5) and treated with aspirin or MG-132 at
various times post-infection (Fig. 4C). Infected, untreated
cells exhibited high levels of both gB and pp65 protein,
whereas no protein was detected in cells pretreated with
aspirin or MG-132, or when the drugs were applied at 6 or 12
hpi. Inhibition of NF-nB activity at 24 hpi revealed only low
levels of gB and pp65 production. When the drugs were
applied at 48 hpi, both gB and pp65 were produced, although
the production of gB was somewhat decreased in cultures
treated with aspirin. The solvent alone controls had no effect
on viral gene expression (data not shown). Western blot
analysis using antibodies specific for IE2-86 revealed that IE
proteins reached near-maximal levels by 24 hpi, demonstrat-
ing that the effects observed at this time point were not due to
an inhibition of MIEP transactivation by the NF-nB inhibitory
compounds. The near normal production of pp65 and gB,
when NF-nB was inhibited at 48 hpi, despite the impairment
of progeny virus production (Fig. 4B), suggests that other
required viral genes are more sensitive to the inhibition of
NF-nB activity.
Treatment of HCMV-infected fibroblasts with BAY11 inhibited
viral replication
Aspirin and MG-132 are widely used to inhibit NF-nB
activation, however, each of these compounds may also have
additional effects on cellular function. To provide additional
support for our observations using aspirin and MG-132,
BAY11 was used to block NF-nB activation (Fig. 5). BAY11
was identified as a novel inhibitor of InBa phosphorylation,
and thus, the release of active NF-nB (Pierce et al., 1997). The
NF-nB inhibitory effects of BAY11 appear irreversible and
specific for InBa (Cahir-McFarland et al., 2004; Pierce et al.,
1997).
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significantly inhibited viral replication, as determined by
fluorescence intensity (Fig. 5A). When fibroblast cultures
were infected and treated with BAY11 at 24 or 48 hpi, a
reduction in viral replication was observed. These results
mirror those observed with cultures treated with aspirin or
MG-132. Cultures pretreated with BAY11 exhibited a 9-fold
increase (68% decrease compared to DMSO-treated cells) in
fluorescence intensity when compared to mock-infected
cultures at 96 hpi; cultures treated with DMSO alone,
however, exhibited a 28-fold increase in fluorescence
intensity over mock-infected cells at the same time point.
Treatment of cultures with BAY11 at 24 hpi and 48 hpi
resulted in respective 14-fold increases (a 50% decrease) in
fluorescence intensity when compared to mock-infected cells
at 96 hpi. These results provide evidence that NF-nB
activity is required for efficient HCMV replication because
the compounds we utilized to inhibit NF-nB activation
function via different mechanisms, with non-overlapping side
effects.
To confirm our previous results indicating that late protein
production was inhibited when drugs were applied prior to
infection or after 24 hpi, but not after 48 hpi, we performed
Western blot analyses using antibodies specific for gB on
infected cell lysates treated with BAY11 (or DMSO control)
at various times post-infection (Fig. 5B). Detection of gB
revealed high levels of this protein at 72 hpi in untreated
samples and samples to which BAY11 was applied 48 hpi; no
gB was detected in cells pretreated with BAY11 or when the
drug was applied 6 or 12 hpi. Very low levels of gB were
detected after the addition of BAY11 at 24 hpi. These results
mirror our observations on the expression of late protein
production in the presence of aspirin and MG-132 (Fig. 4C).
To confirm that IE proteins were produced despite the
addition of BAY11 to infected cultures at 24 and 48 hpi,
Western blot analysis was performed on replicate cell lysates
harvested from cultures treated with BAY 11 at these times
post-infection. Maximal levels of IE2-86 were detected in
cultures treated with BAY11 at 24 and 48 hpi (Fig. 5C). It
should be noted that the concentration of BAY11 used in our
studies (2.5 AM) was less than the concentration used to
inhibit NF-nB activation in other studies (5–10 AM) (Benitah
et al., 2003; Cahir-McFarland et al., 2004; Nakayama et al.,
2004) because of the sensitivity of our fibroblasts to BAY11
at late time points. At 2.5 AM, BAY11 had no cytotoxic
effects at the time points tested, and cells were greater thanFig. 4. Progeny virus production is inhibited by blocking NF-nB activation at late t
grown to confluency in 6-well tissue culture dishes and infected with GFP-HCMV (
drugs were added 24 hpi or 48 hpi. Media were changed, and MEM containing fre
assays performed. (A) Plaques were visualized by fluorescence microscopy (101 di
for each dilution was counted to determine the virus titer (displayed as infectious
experiments were repeated with similar results. A representative experiment is sho
aspirin or MG-132 for 1 h prior to infection with HCMV (MOI 3–5), or the drugs w
identically at each time point. Total cell lysates were collected at 72 hpi, and protein
late HCMV proteins gB and pp65, as well as IE2-86. A monoclonal antibody specif
uninfected fibroblasts. All experiments were repeated with similar results; a represe95% viable as determined by trypan blue (data not shown)
and TUNEL staining (Supplemental Fig. 1).
Decreased viral replication was not due to a block in viral
infectivity
Studies with other herpesviruses have suggested that
inhibition of the phosphatidylinositol 3-kinase (PI3-K) cellular
signaling pathway, which is upstream of NF-nB activation,
significantly reduced infectivity by blocking viral entry
(Naranatt et al., 2003; Wang et al., 2005). To determine if the
block in HCMV replication observed in the presence of NF-nB
inhibitors was due to a similar inhibition of HCMV entry into
fibroblasts, cells were pretreated with aspirin, MG-132, and
BAY11 for 1 h, or left untreated, and infected with BrdU-
labeled HCMV. Confocal immunofluorescence microscopy
was used to visualize infected fibroblasts stained with a
BrdU-specific monoclonal antibody (Fig. 6A). Confocal
microscopy revealed similar numbers of virus particles in the
nuclei of untreated fibroblasts and fibroblasts treated with
aspirin, MG-132, and BAY11. The viral DNA in the nucleus is
marked with a white arrow. When the average number of virus
particles per nucleus (n = 50) was calculated, similar levels of
infectivity were observed following treatment with NF-nB
inhibitory drugs (Fig. 6B). These results provide evidence that
inhibition of the NF-nB pathway did not interfere with HCMV
entry into cells and suggested that the observed effects of these
drugs on HCMV replication occurred at the level of NF-nB-
directed transcriptional control.
Aspirin, MG-132, and BAY11 block NF-jB nuclear
translocation
To confirm that the drugs used in these studies blocked
nuclear translocation of NF-nB, cellular localization of p65
was determined using immunofluorescence microscopy (Fig.
7). Cells were pretreated with aspirin, MG-132, BAY11, or the
drug solvent DMSO and infected with HCMV (MOI 3–5). As
a positive control, untreated cells were infected, and mock-
infected cultures were used as a negative control. Nuclear
translocation of p65 was evident in untreated but infected cells
and infected cells treated with the drug solvent DMSO alone.
However mock-infected cells and cells treated with aspirin,
MG-132, and BAY11 prior to infection revealed predominant
cytoplasmic p65 staining with little or no detectable p65
localized to the nucleus. These data support the role that theimes of infection. Supernatant was collected at 96 hpi from fibroblasts cultures
MOI 3–5). Cultures were either pretreated with aspirin, MG-132, or DMSO, or
sh drugs was added every 24 h. Supernatants were serially diluted and plaque
lution shown) at 60 hpi. (B) The total number of GFP-expressing cells at 60 hpi
units (IU) of virus per milliliter). Mock represents uninfected fibroblasts. All
wn. (C) HEL fibroblasts were untreated, pretreated with the NF-nB inhibitors
ere added to cultures at 6 hpi, 12 hpi, 24 hpi, or 48 hpi. All cultures were treated
levels were analyzed by Western blot analysis using antibodies specific for the
ic for a-tubulin was used to verify equal loading in each lane. Mock represents
ntative experiment is shown.
Fig. 5. The effects of BAY11 on HCMV replication are similar to those observed with other NF-nB inhibitors. (A) Fibroblasts were treated with BAY11 for 1 h prior
to infection with GFP-HCMV, or drugs were added 24 hpi or 48 hpi. Untreated cultures and cultures treated with DMSO alone were used as controls; a mock-
infected culture was used as the negative control. Fluorescence intensity of infected plates was measured every 24 h using a fluorescence plate reader. Results are
displayed as fold-increase (Tstandard deviation) in fluorescence intensity of GFP-HCMV-infected cells over mock-infected cells. The data are the means of three
independent experiments. P values were calculated using Student’s t test and demonstrate a significant increase ( P < 0.005) in both infected cultures when compared
to cultures to which NF-nB inhibitory drugs were added 24 or 48 hpi. (B) HEL fibroblasts were untreated, pretreated with BAY11 for 1 h prior to infection with
HCMV (MOI 3–5), or the drug was added to cultures at the times indicated following infection. Total cell lysates were collected at 72 hpi, and protein levels were
analyzed by Western blot analysis using antibodies specific for the HCMV late protein gB. A monoclonal antibody specific for a-tubulin was used to verify equal
protein loading in each lane.Mock represents uninfected fibroblasts. (C) To demonstrate the normal production of IE proteins in cells to which BAY11 was added 24
and 48 hpi, Western blot analysis was performed on replicate samples harvested at 72 hpi using a monoclonal antibody specific for IE2-86. No IE2-86 protein was
detected in cells pretreated with BAY11. All experiments were repeated with similar results; representative experiments are shown.
I.B. DeMeritt et al. / Virology 346 (2006) 15–3124activation and nuclear translocation of NF-nB plays in multiple
steps in the viral life cycle.
Discussion
HCMV replication in immunocompromised individuals,
such as transplant recipients, congenitally infected neonates,
and AIDS patients, leads to severe disease (Pass, 2001). In thepresent study, we demonstrated that pharmacological agents
that inhibited activation of the NF-nB pathway were capable of
preventing viral replication and release of progeny virus, even
when activation was blocked after the initiation of HCMV
replication. These results contribute to our understanding of the
role NF-nB plays in the viral life cycle.
This present study expands upon work previously per-
formed by Yurochko et al. (1995) demonstrating that
Fig. 6. Decrease in viral replication was not due to a block in infectivity. HEL fibroblasts were pretreated with aspirin, MG-132, and BAY11 and infected with BrdU-
labeled HCMV. Cells were stained for BrdU 3 hpi and visualized by confocal microscopy. Nuclei are shown in red, and BrdU-labeled virus particles are shown in
green. White arrows mark nuclear viral DNA staining. Experiments were repeated with similar results. (B) The average number of BrdU-labeled virus particles per
nucleus was determined by counting all BrdU particles in the nuclei of fifty cells. The experiments were performed in triplicate. Results are presented as the average
number of virus particles per nucleus (Tstandard deviation). Untreated but infected cells were used as the positive control, whereas mock-infected cells were used as
the negative control. No significant difference between untreated and treated cultures was observed. 
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occurred in two distinct phases. The first phase took place
within minutes of infection and lasted for several hours, while
the second phase of NF-nB activation occurred after 12 hpi
and remained elevated throughout the course of infection. Our
recent work elucidated a function for the initial phase of NF-
nB activation by providing evidence that the MIEP was
largely dependent on activated NF-nB for its transactivation at
IE times of infection (DeMeritt et al., 2004). In this study, we
proposed that the initial phase of NF-nB activation functioned
to ‘‘jump-start’’ viral gene expression immediately after
infection. The work presented here details a role for the
second phase of NF-nB activation and leads us to propose that
NF-nB activity is also important for efficient viral replication
and viral maturation.To investigate the role NF-nB plays in the HCMV life cycle,
the pharmacological agents aspirin, MG-132, lactacystin, and
BAY11 were employed; each of these compounds effectively
inhibits NF-nB activation (Cahir-McFarland et al., 2004; Kopp
and Ghosh, 1994; Palombella et al., 1994; Pierce et al., 1997;
Wu et al., 2002; Yin et al., 1998). An important consideration
for our use of these agents was that each impaired NF-nB
activation through a different mechanism: aspirin is the least
specific inhibitor and affects signaling through IKKh and other
factors upstream of NF-nB (Mitchell et al., 1997; Smith et al.,
1993; Yin et al., 1998), MG-132 and lactacystin prevent
degradation of InBa by inhibiting the 26S proteosome complex
(Palombella et al., 1994), and BAY11 prevents the phosphor-
ylation of InBa (Cahir-McFarland et al., 2004; Pierce et al.,
1997). The combination of compounds used in the current
Fig. 7. Aspirin, MG-132, and BAY11 block NF-nB nuclear translocation. The nuclear translocation of NF-nB p65 was analyzed by confocal microscopy 1 hpi in the
presence and absence of NF-nB inhibitory drugs aspirin, MG-132, and BAY11, or the drug solvent DMSO. Untreated but infected cultures were used as the positive
control, and mock-infected cultures served as the negative control. Nuclei are shown in red, and p65 protein is shown in green. Experiments were repeated with
similar results. A representative experiment is shown. 
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significantly decreased levels of MIEP transactivation in the
presence of dominant negative InBa, IKKa, and IKKh
(DeMeritt et al., 2004), provides strong support for the
requirement of NF-nB activity in the viral life cycle in human
fibroblasts. Although the drugs used to inhibit NF-nB may
exert additional effects on cellular physiology, the multiple
approaches utilized to inhibit NF-nB activity suggest that our
observations document the effects mediated by NF-nB on the
transactivation of viral promoters.
The robust inhibition of HCMV replication and maturation
we observed when cells were pretreated with NF-nB inhibitors
prior to infection supports our previous findings that virally-
induced NF-nB is a central factor in viral gene expression.
However, the observation that there was a three-log decrease in
viral replication when the drugs were added at 48 hpi, suggested
that steps in the HCMV life cycle, in addition to IE gene
expression, are affected by the inhibition of NF-nB activity.
Although a more pronounced decrease in viral replication was
observed when cells were pretreated with the NF-nB inhibitors
than when the inhibitors were added at 48 hpi, these data
indicated that HMCV replication can be reduced after a
productive infection has initiated. Therefore, targeting the NF-
nB pathway – in combination with other anti-viral treatments –
may provide an effective means of blocking HCMV replication
in high-risk patients.
The data documenting the inhibition of viral replication by
drugs that block NF-nB activity suggested that one or more
early genes critical for HCMV replication were responsive to
NF-nB activation. While we are currently investigating the
identity of potential NF-nB-responsive early genes, a likely
candidate in our studies is the UL54 DNA polymerase. While
no consensus NF-nB binding sites have been identified in this
promoter, several regions of the promoter sequence (Kerry et
al., 1994) share nucleotide homology with consensus NF-nB
binding sites (nucleotides 98 to 89, 81 to 72, and 3 to+8). Therefore, it is possible that NF-nB transactivates the
UL54 promoter. Studies investigating a potential role for NF-
nB in the transactivation of this promoter are currently being
conducted in our laboratory. Preliminary data suggest that
UL54 mRNA levels are substantially decreased in the presence
of all three NF-nB inhibitory drugs, thus providing a
mechanism for the decrease in viral replication observed when
NF-nB activity was inhibited.
The effects of NF-nB inhibitors on HCMV replication at IE
and early times of infection are explained by the fact that
proteins produced at these times are required for the
completion of the HCMV gene cascade. However, the
observed decrease in viral maturation following inhibition of
NF-nB activity at later times, when IE and early proteins are
present, suggested that promoters for some of the late genes
likely contain NF-nB binding sites. In our hands, pp65 and gB
expression were inhibited when NF-nB activity was blocked at
24 hpi, but not at 48 hpi, suggesting that other late genes are
more sensitive to the inhibition of NF-nB activity. Late
proteins, including pp71, pUL69, and pUL97, have been
demonstrated to be important for efficient viral replication
(Bresnahan and Shenk, 2000; Hayashi et al., 2000; Prichard et
al., 1999). The viral titers produced from cells infected with
mutant viruses lacking these proteins are similar to those we
observed from HEL fibroblasts infected with wild-type HCMV
in the presence of the NF-nB inhibitors. We have not analyzed
the proteome of virions produced in the presence of NF-nB
inhibitors to determine which proteins, if any, are absent; these
studies are currently being addressed in our laboratory.
Our data suggesting a role for NF-nB in the progression of
the HCMV life cycle were supported by Caposio et al. (2004),
who recently demonstrated that IKKh was important for
HCMV MIEP transactivation and viral replication. In addition,
our previous report demonstrating that MG-132 significantly
inhibited IE protein production (DeMeritt et al., 2004) was
confirmed by Gealy et al. (2005). Likewise, efficient replica-
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dependent on the NF-nB pathway (Gregory et al., 2004).
However, the role NF-nB plays in the HCMV life cycle is
controversial, as additional reports suggest that ‘‘classical’’ NF-
nB activity was not required for the transactivation of the
HCMV MIEP (Benedict et al., 2004; Eickhoff and Cotten,
2005; Isomura et al., 2004). The source of the discrepancies
among these studies is unknown but may represent differences
in the cell lines or virus strains used. Regardless, further work
will be needed to appreciate the full significance of the
activation of NF-nB to HCMV pathobiology.
Elevated levels of NF-nB are associated with a number of
pathological states, many of which are similar to diseases
associated with HCMV infection (Baldwin, 2001; Perkins,
2000), suggesting a link between HCMV pathogenesis and the
viral induction of NF-nB. For instance, aberrant levels of NF-nB
are associated with birth defects (reviewed in Aradhya and
Nelson, 2001); could this aberrant NF-nB induction be a
biological mechanism for the pathologies caused by congenital
HCMV infection? In addition, evidence associates HCMV
infection with inflammatory diseases such as atherosclerosis
and restenosis (Blum et al., 1998; Bruggeman, 1999; Brugge-
man et al., 1999; Epstein et al., 1999a, 1999b; Hendrix et al.,
1990; Melnick et al., 1990; Sorlie et al., 2000; Zhu et al., 1999).
Because genes upregulated in atherosclerotic plaques are
mediated by NF-nB, the possibility exists that the induction of
NF-nB in the infected vasculature could be involved in
pathogenesis. Together, our observations implicate a role for
viral-induced NF-nB in multiple steps in the viral life cycle and
provide a possible biological explanation for viral-mediated
disease.
Materials and methods
Cell culture and virus
Primary human embryonic lung (HEL) fibroblasts (passage
13–20) were cultured in Eagle’s minimal essential media
(MEM, Cellgro Mediatech, Inc., Herndon, VA) supplemented
with 10% heat-inactivated fetal bovine serum (FBS, Gemini,
Woodland, CA), penicillin (100 IU/ml), and streptomycin
(100 Ag/ml). In all experiments, either a Toledo strain of
HCMV expressing Green Fluorescent Protein (GFP-HCMV)
(Iwata et al., 1999) or a low passage Towne/E strain of
HCMV (passage 35–42) (Yurochko et al., 1997a) was used.
Unless otherwise stated, all infections were performed with a
multiplicity of infection (MOI) of three to five. Virus stocks
were cultured in HEL fibroblasts grown in Eagle’s MEM
(Cellgro Mediatech, Inc.) supplemented with 4% heat-
inactivated FBS (Gemini), penicillin (100 IU/ml), and
streptomycin (100 Ag/ml).
NF-jB inhibitory drugs
To inhibit NF-nB activation, aspirin (acetylsalicylic acid,
Sigma, St. Louis, MO), MG-132 (Z-Leu-Leu-Leu-al; Sigma),
lactacystin (EMD Biosciences, Inc., La Jolla, CA), andBAY11-7082 (BAY11; EMD Biosciences, Inc.) were resus-
pended in appropriate solvents (1 M Tris [pH 8.0] for aspirin;
dimethyl sulfoxide [DMSO] for MG-132, lactacystin, and
BAY11) and diluted to their appropriate concentrations (3 mM
for aspirin, 2.5 AM for MG-132, lactacystin, and BAY11) in
Eagle’s MEM (Cellgro Mediatech, Inc.) supplemented with 4%
heat-inactivated FBS (Gemini), penicillin (100 IU/ml), and
streptomycin (100 Ag/ml). Titrations of drugs were performed
to determine the optimal doses for use in our studies (data not
shown). For some experiments, the diluted drugs were
incubated with HEL fibroblast cultures for 1 h prior to
infection. After pretreatment, the media were removed, and
cultures were infected with HCMV (MOI 3–5) in drug-
containing media, which were replaced every 24 h. For
experiments in which the NF-nB inhibitory drugs were added
to the cultured cells at various times post-infection, infections
were performed in drug-free media which were replaced every
24 h. For all experiments involving NF-nB inhibitory drugs,
replicate control cultures were treated with identical concentra-
tions of the drug solvents at the same time points. Additionally,
replicate mock-infected cultures were performed to ensure that
the NF-nB inhibitory drugs had no effect on the fluorescence
readings. Cells treated with the NF-nB inhibitory drugs and
drug solvents were tested for cytotoxicity using trypan blue
(Cellgro Mediatech, Inc.) exclusion staining (data not shown)
and TUNEL staining (Supplemental Fig. 1): greater than 95%
of all cells were viable at all time points used in our assays.
Quantification of fluorescence intensity
HEL fibroblasts were cultured in 6-well tissue culture dishes
and, when confluent, infected with GFP-HCMV in the
presence of NF-nB inhibitors, or control compounds. Every
24 hpi, relative fluorescence intensity of HEL cultures infected
with GFP-HCMV was measured using a POLARstar OPTIMA
fluorescence plate reader (BMG Labtech, Inc., Durham, NC)
and FLUOstar OPTIMA software (BMG Labtech, Inc.). Raw
fluorescence data were converted to the fold increase in
fluorescence intensity of each sample over that of mock-
infected cells. P values were calculated using Student’s t test
on three independent replicates of the experiment.
DNA isolation and dot blot analysis
Total cellular DNA was harvested from HCMV-infected
fibroblasts using the Qiagen DNeasy kit (Qiagen, Inc.,
Valencia, CA). DNA was denatured by heating to 100 -C for
10 min in a solution containing 0.4 M NaOH and 10 mM
EDTA. DNA was then spotted onto a Zeta-Probe Blotting
membrane (Bio-Rad Laboratories, Hercules, CA) using a
microfiltration vacuum apparatus (Bio-Rad Laboratories).
Wells were then washed and the DNA cross-linked to the
membrane using ultraviolet light.
A radioactive probe specific for the genomic sequence of
the region from exon 2 to exon 4 of IE1-72 was generated by
PCR on viral DNA isolated from HCMV-infected fibroblasts.
Primers corresponding to exon 2 (sense: ACACGATG-
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CACCATGTCC) (Gerna et al., 1992) were used to amplify
genomic IE1-72. The amplification product of 587 bp
confirmed the presence of the correct intronic sequences in
the PCR product (data not shown). PCR was carried out in the
presence of 1 Al 32P-CTP (ICN Biomedicals, Inc., Irvine, CA)
and, following amplification for 35 cycles (94 -C for 1 min,
57.5 -C for 1 min, 72 -C for 1.5 min), the PCR product was
filtered through a NucTrap probe purification column (Strata-
gene, La Jolla, CA). Hybridization was performed by overnight
incubation of the membrane at 65 -C in a hybridization buffer
(1 mM EDTA, 0.5 M Na2HPO4, 7% SDS) containing the
radioactive probe. The membrane was washed twice with
washing buffer (1 mM EDTA, 0.5 M Na2HPO4) containing 5%
SDS and twice with washing buffer containing 1% SDS for 30
min per wash. Following washing, the membrane was
visualized by autoradiography.
Infectious unit assays
HEL fibroblasts were grown to confluency in 6-well tissue
culture dishes and infected with GFP-HCMV (MOI 3–5) in
the presence or absence of aspirin (3 mM), MG-132 (2.5 AM),
or BAY11 (2.5 AM). Cell supernatants from infected or mock-
treated cells incubated with the NF-nB inhibitory compounds
or the drug solvents were collected at various times post-
infection. Infectious unit assays were performed similarly to
the plaque assay protocol described by Kowalik et al. (1994).
Fresh HEL fibroblasts were grown to confluency in 24-well
dishes and infected with 1 ml of serially diluted virus from the
different treatment groups. Wells were then washed with PBS
(phosphate-buffered saline) and overlayed with 1 methyl-
cellulose (Sigma) containing 1 MEM (Mediatech, Inc.)
supplemented with 4% FBS (Gemini), penicillin (100 IU/
ml), and streptomycin (100 Ag/ml). Infected cells expressing
GFP (each GFP-expressing cell was counted as one infectious
unit of virus) were visualized and counted using fluorescence
microscopy.
Western blot analysis
Infected fibroblast cultures were harvested for Western blot
analysis in Laemmli sample buffer (Bio-Rad Laboratories)
supplemented with 2.5% h-Mercaptoethanol (DeMeritt et al.,
2004). Cell lysates were boiled and SDS-10% polyacrylamide
gel electrophoresis was performed. Equal amounts of protein
were loaded in each lane. Electrophoresed proteins were
transferred to ImmunoBlot polyvinylidene difluoride mem-
branes (BioRad laboratories) and incubated in a blocking
buffer (5% skim milk, 0.1% Tween-20, 1 PBS). Membranes
were incubated with primary antibodies diluted in blocking
buffer and, following incubation, blots were washed with a 1
PBS/0.1% Tween-20 solution. Membranes were then incubated
with a horseradish peroxidase-conjugated secondary antibody
(Amersham Biosciences, Piscataway, NJ) diluted in blocking
buffer. Blots were washed and developed using the ECL+
system (Amersham Biosciences) according to the manufac-turer’s protocol. Monoclonal antibodies specific for HCMV
IE1-72 (6E1) and IE2-86 (12E2) were used previously
(Yurochko et al., 1997a). The monoclonal a-tubulin (TU-02)
antibody (catalog #sc-8035) was obtained from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA). Mouse monoclonal
antibodies specific for the HCMV glycoprotein B (Abcam,
Inc., Cambridge, MA; catalog #ab6499) and pp65 (Virusys
Corporation, Sykesville, MD; catalog #CA003-100) were also
used in these studies.
Bromodeoxyuridine-labeling of HCMV
To visualize viral entry into HEL fibroblasts, HCMV
particles were labeled with 5-bromo-2V-deoxyuridine (BrdU;
Calbiochem, San Diego, CA) according to the protocol of
Rosenke and Fortunato (2004). Briefly, confluent HEL
fibroblasts were infected with the Towne/E strain of HCMV
and incubated overnight in Eagle’s MEM (Cellgro Mediatech,
Inc.) supplemented with 4% heat-inactivated FBS (Gemini),
penicillin (100 IU/ml), and streptomycin (100 Ag/ml). When
cytopathic effects were observed in 80–90% of the cells, media
were replaced with fresh media containing 10 AM BrdU. After
incubation for 48 h, additional BrdU was added to cultures, and
cells were incubated for another 24 h before virus was
harvested.
To visualize viral entry into cells, HEL fibroblasts were
grown on glass coverslips and treated with aspirin (3 mM),
MG-132 (2.5 AM), or BAY11 (2.5 AM), or left untreated, for 1
h prior to infection. Cells were infected with BrdU-labeled
HCMV and infection was allowed to proceed for 3 h.
Following infection, coverslips were washed with PBS and
cells were fixed in 3% paraformaldehyde for 10 min. Cells
were then permeabilized with 1% Triton X-100, followed by
treatment with 4 N HCl to expose the BrdU residues.
Coverslips were blocked with PBS containing 1% FBS
(Gemini) and then treated with a mouse monoclonal anti-
BrdU (Ab-3) antibody (Calbiochem; catalog #NA61) followed
by a FITC-labeled goat anti-mouse secondary antibody (Santa
Cruz Biotechnology, Inc.; catalog #sc-2010). Nuclei were
stained with TO-PRO-3 iodide (Molecular Probes, Inc.,
Eugene, OR; catalog #T3605). Cells were visualized by
confocal microscopy.
Visualization of NF-jB p65 localization
Fibroblasts were grown on glass coverslips and treated for
1 h with aspirin, MG-132, BAY11, or the drug solvent
DMSO; replicate untreated and mock-infected cultures were
also used. Cells were infected with HCMV Towne/E (MOI
3–5) for 1 h. Following infection, coverslips were washed
with PBS, cells were fixed in 3% formaldehyde and
permeabilized with 1% Triton X-100. Coverslips were
blocked in a 30% FBS blocking solution containing 1%
BSA and 0.01% Tween-20 in PBS prior to the addition of a
primary rabbit polyclonal antibody specific for NF-nB p65
(Santa Cruz Biotechnology; catalog #sc-109). Following
incubation, coverslips were washed with PBS, and a FITC-
I.B. DeMeritt et al. / Virology 346 (2006) 15–31 29conjugated goat anti-rabbit secondary antibody (Santa Cruz
Biotechnology; catalog #sc-2012) was applied. Nuclei were
stained using TO-PRO-3 iodide (Molecular Probes, Inc.;
catalog #T3605), and coverslips were mounted on glass
slides with the SlowFade Light Anti-Fade kit (Molecular
Probes, Inc.; catalog #S7461). Cells were visualized using
confocal microscopy.
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